Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358: 903–11.
   PubMed Web of Science ®Google Scholar
• Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci. 2002;323: 171–80.
   Google Scholar
• Weinblatt ME. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1995;34(Suppl 2):43–8.
   PubMedGoogle Scholar
• Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328–46.
   PubMed Web of Science ®Google Scholar
• Tsuzuki K. Role of mizoribine in renal transplantation. Pediatr Int. 2002;44:224–31.
   PubMedGoogle Scholar
• Honda M. Nephrotic syndrome and mizoribine in children. Pediatr Int. 2002;44:210–6.
   PubMedGoogle Scholar
• Tanaka H, Tsugawa K, Tsuruga K, Suzuki K, Nakahata T, Ito E, et al. Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol. 2004;62:412–7.
   Google Scholar
• Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the associ-ation between peak mizoribine concentration and clinical effi-cacy. Mod Rheumatol. 2007;17:206–12.
   PubMedGoogle Scholar
• Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int. 2002;44:196–8.
   PubMed Web of Science ®Google Scholar
• Pankiewicz KW, Patterson SE, Black PL, Jayaram HN, Risal D, Goldstein BM, et al. Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IM-PDH)-the major therapeutic target. Curr Med Chem. 2004;11: 887–900.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y, Honma M, Shichikawa K, Miyamoto T, Hirose J, Nobunaga M, et al. Clinical evaluation of an immunosuppressant mizoribine in the treatment of rheumatoid arthritis (in Japanese). J Clin Exp Med. 1991;156:811–31.
   Google Scholar
• Shiokawa Y, Honma M, Shichikawa K, Miyamoto T, Hirose J, Nobunaga M, et al. Clinical effectiveness of mizoribine on rheumatoid arthritis. A double-blid comparative study using lo-benzarit disodium as a standard drug (in Japanese). Inflammation. 1991;11:375–96.
   Google Scholar
• Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int. 2002;44:205–9.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the devel-opment of a disease activity score. Ann Rheum Dis. 1990;49: 916–20.
   Google Scholar
• van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/ International League against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.
   Google Scholar
• Ziebland S, Fitzpatrick R, Jenkinson C, Mowat A. Comparison of two approaches to measuring change in health status in rheu-matoid arthritis: the Health Assessment Questionnaire (HAQ) and modified HAQ. Ann Rheum Dis. 1992;51:1202–5.
   PubMed Web of Science ®Google Scholar
• Lubeck DP. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care. 2002;8:811–20.
   PubMedGoogle Scholar
• Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a pre-dictor of the degree of joint destruction during the 6 months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852–8.
   PubMed Web of Science ®Google Scholar
• Ainola MM, Mandelin JA, Liljestrom MP, Li TF, Hukkanen MV, Konttinen YT. Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-lbeta. Clin Exp Rheumatol. 2005;23:644–50.
   PubMed Web of Science ®Google Scholar
• Munster T, Furst DE. Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA). Clin Exp Rheumatol. 1999;17:529–36.
   Google Scholar
• Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfa-salazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66:235–41.
   PubMed Web of Science ®Google Scholar
• Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Com-bination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, con-trolled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082–8.
   PubMedGoogle Scholar
• Gerards AH, Landewe RB, Prins AP, Bruyn GA, Goei The HS, Laan RF, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo con-trolled trial. Ann Rheum Dis. 2003;62:291–6.
   PubMed Web of Science ®Google Scholar
• Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination lefiunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol. 2004;31:1521–31.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka H, Hara M, et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol. 2006;16:214–9.
   PubMedGoogle Scholar
• Fujii T, Suwa A, Nojima T, Mimori T, Hirakata M. The addi-tional use of mizoribine in patients with methotrexate-resistant rheumatoid arthritis (in Japanese). Pharma Medica. 2004;22: 73–9.
   Google Scholar
• Nishimura K, Itoh K, Kuga Y, Uchida S, Nishino J, Nakamura N, et al. Prevention of joint destraction in rheumatoid arthritis patients receiving combination methotrexate and mizoribine therapy: a two-year, multicenter open-comparison study to methotrexate monotherapy. Prog Med. 2006;26:2163–72.
   Google Scholar
• Tsukano M, Tomoda K, Nakamura T, Higashi S. The efficacy and safety of additional use of mizoribine in patients with metho-trexate-resistant rheumatoid arthritis (in Japanese). Pharma Medica. 2007;25:96–101.
   Google Scholar
• Tanaka H, Mine T, Tani Y, Chagawa K, Taguchi T. Combination therapy with methotrexate and mizoribine for patients with rheumatoid arthritis (in Japanese). Orthop Traumatol. 2008;57: 439–42.
   Google Scholar
• Tokuda M, Dobashi H, Hiraishi T, Mitsunaka H, Takahara J, Hirohata M. Effect of mizoribine pulse therapy on the disease activity of rheumatoid arthritis refractory to the treatment with methotrexate (in Japanese). Rheumatology. 1998;20:519–26.
   Google Scholar
• Kohriyama KYH, Aoyama T. Efficacy of combination pulse therapy with methotrexate and mizoribine for patients with rheumatoid arthritis showing escape phenomenon to low-dose methotrexate therapy (in Japanese). Clin Rheumatol. 2003;15: 227–34.
   Google Scholar
• Murai T, Arai K, Fujisawa J, Kondo N, Habu T. Evaluation of combination pulse therapy with methotrexate and mizoribine for patients with methotrexate-resistant rheumatoid arthritis (in Japanese). J Chubu Rheum Assoc. 2006;37:80–1.
   Google Scholar
• Fox RI, Morgan SL, Smith HT, Robbins BA, Choc MG, Baggott JE. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford). 2003;42:989–94.
   PubMed Web of Science ®Google Scholar
• Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993;5: 763–73.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.
   Google Scholar
• van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277–92.
   Google Scholar
• Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol. 1999;11:226–32.
   PubMedGoogle Scholar
• Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:2153–61.
   PubMed Web of Science ®Google Scholar